Gilead is a Fortune 500 biopharma developing therapies for life-threatening diseases. This AR focuses on Gilead's greatest asset—its diverse and talented employees. Following a year of acquisitions and challenging clinical trials, this book reminds investors and partners that the driving force behind Gilead's innovation and success is still as strong as ever.